Zealand Pharma A/S

Zealand Pharma A/S, a Biological Product (except Diagnostic) Manufacturing company headquartered in DK, reported total carbon emissions of approximately 38,361,000 kg CO2e in 2025. This includes about 72,000 kg CO2e from Scope 1 emissions, 154,000 kg CO2e from Scope 2 (market-based), and 38,135,000 kg CO2e from Scope 3 emissions. Key Scope 3 contributors in 2025 were purchased goods and services (approximately 28,756,000 kg CO2e) and investments (approximately 3,120,000 kg CO2e).

In 2024, the company's total emissions were approximately 27,697,000 kg CO2e, with Scope 1 at about 131,000 kg CO2e, Scope 2 (market-based) at approximately 398,000 kg CO2e, and Scope 3 at about 27,168,000 kg CO2e. For 2023, total emissions were around 25,589,000 kg CO2e, comprising approximately 144,000 kg CO2e from Scope 1, 402,000 kg CO2e from Scope 2 (market-based), and 24,283,000 kg CO2e from Scope 3.

Zealand Pharma has committed to several Science Based Targets initiative (SBTi) aligned goals. It aims to reduce absolute Scope 1 and Scope 2 GHG emissions by 46.2% by 2031, using a 2024 base year. Additionally, the company commits to reduce Scope 3 GHG emissions from investments by 55.8% per EUR value added within the same timeframe. Zealand Pharma also has a commitment that 80.0% of its suppliers, by emissions covering purchased goods and services, will have science-based targets by 2029. These near-term targets are classified as consistent with reductions required to keep warming to 1.5°C. Zealand Pharma is also committed to Net-Zero.